| Literature DB >> 35784104 |
Mohammed Alshakka1, Wafa Badullah2, Abdullah Al-Dhuraibi3, Sara Alshagga4, Mohamed Izham Mohamed Ibrahim5.
Abstract
Using medicines associated with adverse drug reactions (ADRs) might cause serious health complications. The pharmacist plays a unique role in monitoring ADRs, either by themselves or with the assistance of other health-care professionals, to diminish the hazards of ADRs by distinguishing, reporting, and evaluating any proposed ADRs. To train future pharmacists who have adequate knowledge of ADRs and related aspects, it is highly recommended to introduce the WHO-ISoP pharmacovigilance (PV) in the core curriculum. In this article, we shared the suggested curriculum in Aden University. It is based on comprehensive outlines and reference books that offer a broad view of all aspects related to PV. A brief student course evaluation was carried out. Fifty students participated in the survey. Students expressed the importance of the course and indicated that they wanted to know more about the types of ADRs and common medication errors. Some of them lacked an understanding of the causal relationship between ADRs and risk assessment and not familiar with the reporting forms. They suggested for PV awareness programs for health-care staff and public. The curriculum should be tailored according to the country's needs because each country has its own medication safety issues and PV program. To reach the ultimate objective, this article reports the initiative to develop PV proficiencies in a university setting. Copyright:Entities:
Keywords: Adverse drug reactions; Yemen; curriculum; pharmacovigilance; pharmacy education
Year: 2022 PMID: 35784104 PMCID: PMC9245919 DOI: 10.4103/jpbs.JPBS_532_20
Source DB: PubMed Journal: J Pharm Bioallied Sci ISSN: 0975-7406
Content of the current clinical pharmacy syllabus for pharmacy undergraduate students at Aden University
| Contents | Number of hours |
|---|---|
| Clinical PKs | 8 |
| An introduction to the concepts of clinical PKs and therapeutic drug monitoring | |
| Fundamental parameters, specifically volume of distribution, clearance, elimination rate constant (K) and half-life, with examples of most common drugs | |
| Pharmacokinetic calculations | |
| Pharmacokinetic case studies | |
| Pharmacokinetic interaction | |
| DIs | 3 |
| Definition and mechanism | |
| Drugs commonly involved in DIs | |
| People most susceptible to DIs | |
| The role of the pharmacist to reduce DIs | |
| ADRs | 4 |
| Definition, types, mechanism, and epidemiology | |
| Predisposing factors | |
| Deduction and reporting | |
| Presentations and discussions by students | |
| Case reports and cohort studies | |
| Case-control studies, spontaneous reporting | |
| Clinical laboratory data | 8 |
| Importance of reference ranges for biochemical and hematological values | |
| Monitoring of blood tests and their reliability | |
| Most common disease induced laboratory value changes | |
| Most common drugs and food induced laboratory value changes | |
| Practical experiments | |
| Drug information systems | 8 |
| Method of gathering and using medical and pharmaceutical information | |
| Type of sources for drugs and poisons (primary, secondary, etc.) | |
| Retrieving, analyzing, and evaluating information | |
| The use of computer short courses | |
| Understanding clinical trials | |
| Pharmacogenomics | 3 |
| Introduction and concept | |
| Human drug response | |
| Polymorphisms of drug metabolism | |
| Disease-associated polymorphisms | |
| Therapeutics | 20 |
| Most common cardiovascular diseases | |
| Most common gastrointestinal diseases | |
| Most common respiratory diseases | |
| Most common skin diseases | |
| Most common endocrine diseases | |
| Most common central nervous system diseases | |
| Most common urological problems | |
| Infectious tropical diseases in Yemen | |
| Case studies | 8 |
| Heart failure, myocardial infarction, and angina | |
| Hypertension | |
| Acute renal failure | |
| Peptic ulcer | |
| Epilepsy | |
| Hospital practice | |
| Attend ward rounds and/or morning meetings (if available) | |
| Writing medical history and understanding the terms and acronyms | |
| Interpret admission reports and relevance of investigation | |
| Study treatment protocols and report on possible contraindication, DI, and inappropriate indication | |
| PKs: Pharmacokinetics, DIs: Drug interaction, ADRs: Adverse drug reactions |
Outline of the main aspects and skills that form a pharmacovigilance core syllabus for university education based on the WHO pharmacovigilance curriculum
| Main aspect | Knowledge | Skills | Attitude | Examples of teaching methods |
|---|---|---|---|---|
| Realizing the value of PV | Case study of a patient admitted to hospital due to serious ADRs | Identifying ADRs and their effect on patients | Broad-mind perspective about the consequences of drug usage in pharmacotherapy | Historical examples of ADRs |
| Patient meeting | ||||
| Avoiding the ADRs | Overall hazard factors, Specific hazard factors, Management strategies and protection information | Selecting proper drug therapy | Harmless advising/dispensing | Problem resolving simulating of a situation and participation in a role-playing exercise |
| ADR monograph | ||||
| Identifying ADRs | ADR categorization | Clinical analysis | Realization of expected and unexpected ADRs | ADR report evaluation |
| Hazard factors | Causality analysis | Prescribing safety evaluation training time | ||
| Confounding factors | ||||
| Epidemiology | ||||
| Proper ADR management | ADR categorization significance Severity | Select correct activities, patients and HCP communications | Evaluating hazard-benefit equilibrium in a specific patient | |
| Reporting of ADR data | ||||
| Reporting ADRs | Boundaries of premarketing stage | Distinguishing ADRs in practice | Obligation for sharing (reporting) of ADRs | ADR reporting task |
| Significance of ADR reporting | Integral reporting form | |||
| Documentation of ADRs |
HCP: Healthcare professional, ADRs: Adverse drug reactions, PV: Pharmacovigilance